Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.
McPhee F, Hernandez D, Zhou N, Yu F, Ueland J, Monikowski A, Chayama K, Toyota J, Izumi N, Yokosuka O, Kawada N, Osaki Y, Hughes EA, Watanabe H, Ishikawa H, Kumada H.
McPhee F, et al. Among authors: ueland j.
Antivir Ther. 2014;19(5):479-90. doi: 10.3851/IMP2729. Epub 2014 Jan 22.
Antivir Ther. 2014.
PMID: 24448487